Pharmacology Core

CFAR药理学核心将支持国内和国际研究，其总体目标是 优化抗逆转录病毒药物的使用。核心将支持CFAR的创新转化研究 investigators.艾滋病毒治疗的复杂性，其中包括几类不同的特点， 抗逆转录病毒药物，强调需要精心设计的最先进的药理学研究。的 药理学核心及其主任在艾滋病毒药理学研究方面有20多年的经验， 齐多夫定是FDA唯一批准的治疗HIV-1感染的药物。核心有三个 具体目标包括： 1.通过开发和应用创新或专业的药理学分析提供服务。的 Core在开发用于测量细胞和靶点药物的新型检测方法方面拥有广泛的专业知识 组织和用于测量高度结合的药物如HIV-1蛋白酶的未结合部分 抑制剂; 2.为优化抗逆转录病毒药物的使用而进行的国内和国际研究。的 核心将继续设计和实施药代动力学和药效学研究， 包括妇女、孕妇、儿童和特定种族的人群; B）新型药物 包括CCR 5和整合酶抑制剂，c）旨在确定 药理学因素预测结果，d）与国内和国际药物相互作用相关的药物相互作用研究 国际人群（即疟疾或结核病患者）; 3.通过指导和培训艾滋病毒领域的初级临床科学家开展教育和外联活动 药理学研究核心与国际核心互动，优化培训， 对国际研究感兴趣的学生、研究员和研究生研究人员。核心也将 作为CFAR调查人员与学院内其他项目合作的渠道， 药学包括膜转运蛋白的药物遗传学。核心 参与严格的QA/QC计划，以确保优质服务。药理学中的试验 核心包括大多数已批准的抗逆转录病毒药物的方法，包括核苷类药物的细胞内方法 非核苷类逆转录酶抑制剂的血浆测定和血浆（未结合和 蛋白酶抑制剂的组织测定。其他分析方法可用于沙利度胺和 抗CMV药物

The CFAR Pharmacology Core will support domestic and international research with the overarching goal of optimizing antiretroviral drug use. The Core will support innovative translational research of CFAR investigators. The complexity of HIV therapy, which includes the distinct characteristics of several classes of antiretroviral drugs, underscores the need for well designed state of the art pharmacology research. The Pharmacology Core and its Director have over 20 years of experience in HIV pharmacology research that stems back to when zidovudine was the only FDA approved drug for HIV-1 infection. The Core has three specific aims including: 1. Service through development and application of innovative or specialized pharmacological assays. The Core has extensive expertise in the development of novel assays for measuring drugs in cells and target tissues and for measuring the unbound fraction of highly bound drugs such as the HIV-1 protease inhibitors; 2. Research for domestic and international research with the goal of optimizing antiretroviral drug use. The Core will continue to design and implement pharmacokinetic and pharmacodynamic studies for a) distinct populations including women, pregnant women, children and those of specific ethnicities; b) novel drugs including CCR5 and integrase inhibitors, c) translational research aimed at determining which pharmacological factors predict outcomes, d) and drug-drug interaction studies relevant to domestic and international populations (i.e. for patients with malaria or tuberculosis); 3. Education and outreach through mentoring and training of junior clinical scientists in the area of HIV pharmacology research. The Core interacts with the International Core to optimize the training of students, fellows and post-graduate researchers interested in international research. The Core will also serve as a conduit for CFAR investigators to collaborate with other programs within the School of Pharmacy including the program on Pharmacogenetics of Membrane Transporters. The Core participates in rigorous QA/QC programs to ensure quality services. Assays within the Pharmacology Core include methods for most approved ARV drugs including intracellular methods for nucleoside analogues, plasma assays for non-nucleoside reverse transcriptase inhibitors and plasma, unbound and tissue assays for the protease inhibitors. Additional analytical methods are available for thalidomide and anti-CMV drugs